MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 462707 | Name: CD4 (81-92)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CD4 (81-92) is a peptide that was previously found to inhibit gp120 binding, HIV-1 infectivity, and syncytium formation.

Chemical Structure

CD4 (81-92)
CAS#126144-46-5

Theoretical Analysis

MedKoo Cat#: 462707

Name: CD4 (81-92)

CAS#: 126144-46-5

Chemical Formula: C62H96N14O26S

Exact Mass: 1484.6341

Molecular Weight: 1485.58

Elemental Analysis: C, 50.13; H, 6.51; N, 13.20; O, 28.00; S, 2.16

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Tyicevedqkee; CD4 (81-92)
IUPAC/Chemical Name
L-Glutamic acid, N-(N-(N2-(N2-(N-(N-(N-(N-(N-(N-(N-L-threonyl-L-tyrosyl)-L-isoleucyl)-L-cysteinyl)-L-alpha-glutamyl)-L-valyl)-L-alpha-glutamyl)-L-alpha-aspartyl)-L-glutaminyl)-L-lysyl)-L-alpha-glutamyl)-
InChi Key
AZDASIIAIPAELA-UCEFLIQFSA-N
InChi Code
InChI=1S/C62H96N14O26S/c1-6-29(4)50(76-57(96)39(73-59(98)48(65)30(5)77)25-31-10-12-32(78)13-11-31)61(100)74-41(27-103)58(97)69-37(17-22-45(84)85)55(94)75-49(28(2)3)60(99)70-36(16-21-44(82)83)54(93)72-40(26-47(88)89)56(95)68-34(14-19-42(64)79)52(91)66-33(9-7-8-24-63)51(90)67-35(15-20-43(80)81)53(92)71-38(62(101)102)18-23-46(86)87/h10-13,28-30,33-41,48-50,77-78,103H,6-9,14-27,63,65H2,1-5H3,(H2,64,79)(H,66,91)(H,67,90)(H,68,95)(H,69,97)(H,70,99)(H,71,92)(H,72,93)(H,73,98)(H,74,100)(H,75,94)(H,76,96)(H,80,81)(H,82,83)(H,84,85)(H,86,87)(H,88,89)(H,101,102)/t29-,30+,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1
SMILES Code
CC[C@@H]([C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCCCN)=O)CCC(N)=O)=O)CC(O)=O)=O)CCC(O)=O)=O)C(C)C)=O)CCC(O)=O)=O)CS)=O)NC([C@@H](NC([C@H]([C@H](O)C)N)=O)Cc1ccc(O)cc1)=O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,485.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kalyanaraman VS, Rausch DM, Osborne J, Padgett M, Hwang KM, Lifson JD, Eiden LE. Evidence by peptide mapping that the region CD4(81-92) is involved in gp120/CD4 interaction leading to HIV infection and HIV-induced syncytium formation. J Immunol. 1990 Dec 15;145(12):4072-8. PMID: 1701782. 2: Lifson JD, Rausch DM, Kalyanaraman VS, Hwang KM, Eiden LE. Synthetic peptides allow discrimination of structural features of CD4(81-92) important for HIV-1 infection versus HIV-1-induced syncytium formation. AIDS Res Hum Retroviruses. 1991 Jun;7(6):521-7. doi: 10.1089/aid.1991.7.521. PMID: 1931230. 3: Rausch DM, Lifson JD, Padgett MP, Chandrasekhar B, Lendvay J, Hwang KM, Eiden LE. CD4(81-92)-based peptide derivatives. Structural requirements for blockade of HIV infection, blockade of HIV-induced syncytium formation, and virostatic activity in vitro. Biochem Pharmacol. 1992 Apr 15;43(8):1785-96. doi: 10.1016/0006-2952(92)90711-q. PMID: 1575773. 4: Rausch DM, Hwang KM, Padgett M, Voltz AH, Rivas A, Engleman E, Gaston I, McGrath M, Fraser B, Kalyanaraman VS, et al. Peptides derived from the CDR3-homologous domain of the CD4 molecule are specific inhibitors of HIV-1 and SIV infection, virus-induced cell fusion, and postinfection viral transmission in vitro. Implications for the design of small peptide anti-HIV therapeutic agents. Ann N Y Acad Sci. 1990;616:125-48. doi: 10.1111/j.1749-6632.1990.tb17834.x. PMID: 2078014. 5: Chang DK, Liang CC. Influence of bulky side chains of amino acids on the solution conformation of peptide fragment (81-92) derivatives of CD4, TYICEVEDQKEE, as studied by NMR spectroscopy and molecular modeling. Biochim Biophys Acta. 1994 Apr 13;1205(2):262-7. doi: 10.1016/0167-4838(94)90243-7. PMID: 8155707. 6: Chang DK, Chien WJ, Cheng SF. Characterization of conformation and dynamics of CD4 Fragment (81-92) TYICEVEDQKEE and its benzylated derivative by 1H NMR spectroscopy and molecular modeling: Relevance of conformation to biological function. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Mar 1;11(3):222-32. doi: 10.1097/00042560-199603010-00002. PMID: 8603258. 7: Repke H, Gabuzda D, Palù G, Emmrich F, Sodroski J. Effects of CD4 synthetic peptides on HIV type I envelope glycoprotein function. J Immunol. 1992 Sep 1;149(5):1809-16. PMID: 1354681. 8: Nara PL, Hwang KM, Rausch DM, Lifson JD, Eiden LE. CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle. Proc Natl Acad Sci U S A. 1989 Sep;86(18):7139-43. doi: 10.1073/pnas.86.18.7139. PMID: 2789382; PMCID: PMC298011. 9: Lasarte JJ, Sarobe P, Golvano J, Prieto I, Civeira MP, Gullón A, Sarin PS, Prieto J, Borrás-Cuesta F. CD4-modified synthetic peptides containing phenylalanine inhibit HIV-1 infection in vitro. J Acquir Immune Defic Syndr (1988). 1994 Feb;7(2):129-34. PMID: 8301524. 10: Prieto I, Lasarte JJ, Sarobe P, Golvano J, Civeira MP, Gullón A, Prieto J, Borrás-Cuesta F. Further insights on the inhibition of HIV type 1 infection in vitro by CD4-modified synthetic peptides containing phenylalanine. AIDS Res Hum Retroviruses. 1996 Jul 20;12(11):1023-30. doi: 10.1089/aid.1996.12.1023. PMID: 8827218. 11: Jai-nhuknan J, Cassady CJ. Negative ion postsource decay time-of-flight mass spectrometry of peptides containing acidic amino acid residues. Anal Chem. 1998 Dec 15;70(24):5122-8. doi: 10.1021/ac980577n. PMID: 9868910.

View History

Arthrytin

Arthrytin